SproutNews logo

MannKind, New Labeling Approved by FDA, Recent Analysts Price Targets

NEW YORK, NY / ACCESSWIRE / October 16, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The company’s only approved product, Afrezza, is a rapid-acting inhaled insulin that is used to control high blood sugar in in adults with type 1 and type 2 diabetes.

Afrezza received regulatory approval from the FDA in June 2014, and has been available by prescription in the United States since February 2015. Afrezza relies on MannKind’s proprietary Technosphere technology, a drug delivery platform that allows for the oral inhalation of a range of therapeutics.

The Traders News Source prior coverage of MannKind, published September 5, 2017, focused on Afrezza sales after the termination of the Sanofi agreement, the company’s cash reserves and burn rate. Since our prior report, the shares are up more than 184 percent and there are multiple catalysts to note.

What exactly are the catalysts driving MNKD shares, and analysts target price READ MORE

Copy and paste to your browser may be required to view the report – http://bit.ly/2yMlVEy-MNKD-Report

Afrezza is used to improve glycemic control in adult patients with diabetes. The product consists of a dry powder formulation of human insulin that is delivered by a small portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and delivers insulin quickly to the bloodstream, achieving peak insulin levels within 12 to 15 minutes of administration.

MannKind management feels that its proprietary Technosphere technology is a candidate for delivery of many drug compounds. The company is also looking past Afrezza with other potential drugs in its pipeline.

Discover other potentials for Technosphere, and review all the MNKD pipeline drugs here READ MORE

Copy and paste to your browser may be required to view the report – http://bit.ly/2yMlVEy-MNKD-Report

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Ivan Neilson, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at:
editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 477881

Go Top